With $23M, Flagship-Backed Sigilon Protects Protein-Producing Cells

07:00 EDT 21 Jun 2017 | Xconomy

Companies have been trying for years, if not decades, to find a way to encapsulate cells for therapeutic use in a way that protects them from the body’s reactions. Sigilon Therapeutics, a Cambridge, MA-based biotech, announced today it has raised $23.5 million from Flagship Pioneering to take its technology to clinical trials. The company has […]

Original Article: With $23M, Flagship-Backed Sigilon Protects Protein-Producing Cells


More From BioPortfolio on "With $23M, Flagship-Backed Sigilon Protects Protein-Producing Cells"

Quick Search


Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Clinical Approvals
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...